News stories about Aradigm (NASDAQ:ARDM) have been trending somewhat positive recently, AlphaOne reports. The research group, a service of Accern, scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. AlphaOne ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aradigm earned a news impact score of 0.04 on AlphaOne’s scale. AlphaOne also assigned news articles about the company an impact score of 50 out of 100, meaning that recent media coverage is somewhat likely to have an impact on the stock’s share price in the near future.

Here are some of the news articles that may have impacted Alpha One Sentiment Analysis’s rankings:

Aradigm (NASDAQ:ARDM) traded down 2.9520% during trading on Friday, reaching $1.2131. 65,824 shares of the company’s stock traded hands. Aradigm has a 12 month low of $0.78 and a 12 month high of $7.19. The company’s market cap is $17.95 million. The firm’s 50 day moving average is $1.27 and its 200 day moving average is $2.21.

Aradigm (NASDAQ:ARDM) last posted its earnings results on Monday, May 15th. The company reported ($0.25) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.18. The company had revenue of $1.69 million for the quarter. Aradigm had a negative net margin of 32,717.14% and a negative return on equity of 220.57%. Analysts anticipate that Aradigm will post ($1.10) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Aradigm (ARDM) Receives Daily Media Sentiment Score of 0.04” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at

Aradigm Company Profile

Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies.

5 Day Chart for NASDAQ:ARDM

Receive News & Stock Ratings for Aradigm Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aradigm Co. and related stocks with our FREE daily email newsletter.